| Biallelic variants in the synaptic vesicle glycoprotein 2 A are associated with epileptic encephalopathy. | Biallelic variants in the synaptic vesicle glycoprotein 2 A are associated with epileptic encephalopathy.
Al-Maawali A, Al-Murshedi F, Al-Futaisi A, Mansy A, Al-Habsi A, Girisha KM., | 02/16/2024 |
| Reductions in synaptic marker SV2A in early-course Schizophrenia. | Reductions in synaptic marker SV2A in early-course Schizophrenia.
Yoon JH, Zhang Z, Mormino E, Davidzon G, Minzenberg MJ, Ballon J, Kalinowski A, Hardy K, Naganawa M, Carson RE, Khalighi M, Park JH, Levinson DF, Chin FT. | 05/8/2023 |
| Loss of SV2A promotes human neural stem cell apoptosis via p53 signaling. | Loss of SV2A promotes human neural stem cell apoptosis via p53 signaling.
Yu H, Han Y, Cui C, Li G, Zhang B. | 02/28/2023 |
| Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants. | Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants.
Badura-Stronka M, Kuszel Ł, Wencel-Warot A, Cudnoch K, Wołyńska K, Rutkowska K, Steinborn B, Płoski R. | 02/24/2023 |
| Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer. | Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer.
Guan B, Zhou N, Wu CY, Li S, Chen YA, Debnath S, Hofstad M, Ma S, Raj GV, He D, Hsieh JT, Huang Y, Hao G, Sun X., Free PMC Article | 01/8/2022 |
| Differentiation of two human neuroblastoma cell lines alters SV2 expression patterns. | Differentiation of two human neuroblastoma cell lines alters SV2 expression patterns.
Lekholm E, Ceder MM, Forsberg EC, Schiöth HB, Fredriksson R., Free PMC Article | 10/9/2021 |
| In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. | In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
Mecca AP, Chen MK, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, Wyk BCV, Varma P, Arnsten AFT, Huang Y, Carson RE, van Dyck CH., Free PMC Article | 06/5/2021 |
| Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [(11) C]UCB-J positron emission tomography study. | Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [(11) C]UCB-J positron emission tomography study.
Finnema SJ, Toyonaga T, Detyniecki K, Chen MK, Dias M, Wang Q, Lin SF, Naganawa M, Gallezot JD, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE. | 02/6/2021 |
| Expression of SV2A in brain tissue predicts adverse events following levetiracetam in patients with brain tumor-related epilepsy. | Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
Romoli M, Mandarano M, Romozzi M, Eusebi P, Bedetti C, Nardi Cesarini E, Verzina A, Calvello C, Loreti E, Sidoni A, Giovenali P, Calabresi P, Costa C. | 02/1/2020 |
| SV2 was highly expressed in neuroblastoma (NB) and can thus be useful marker in NB diagnostics. VMAT1 and VMAT2 were also expressed in NB but similar to syn less reliable as tumor markers. | Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma.
Georgantzi K, Tsolakis AV, Jakobson Å, Christofferson R, Janson ET, Grimelius L. | 01/25/2020 |
| Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. | Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.
Bandala C, Cortés-Algara AL, Mejía-Barradas CM, Ilizaliturri-Flores I, Dominguez-Rubio R, Bazán-Méndez CI, Floriano-Sánchez E, Luna-Arias JP, Anaya-Ruiz M, Lara-Padilla E., Free PMC Article | 06/11/2016 |
| SV2A expression in the bladder urothelium increases after BoNT-A injection. | Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome.
Liu HT, Chen SH, Chancellor MB, Kuo HC., Free PMC Article | 05/21/2016 |
| the way LEV analogues may interact with SV2A | Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis.
Lee J, Daniels V, Sands ZA, Lebon F, Shi J, Biggin PC., Free PMC Article | 11/14/2015 |
| agents that act on the conformation of SV2A might hold great potential in the search for new SV2A-based anticonvulsant therapies | Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.
Daniels V, Wood M, Leclercq K, Kaminski RM, Gillard M., Free PMC Article | 04/4/2015 |
| The newly identified galactose transport capability of SV2A may have an important role in regulating/modulating synaptic function. | The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae.
Madeo M, Kovács AD, Pearce DA., Free PMC Article | 02/14/2015 |
| The SV2A/FE65 interaction might play a role in synaptic signal transduction. | Amyloid beta a4 precursor protein-binding family B member 1 (FE65) interactomics revealed synaptic vesicle glycoprotein 2A (SV2A) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) as new binding proteins in the human brain.
Nensa FM, Neumann MH, Schrötter A, Przyborski A, Mastalski T, Susdalzew S, Looβe C, Helling S, El Magraoui F, Erdmann R, Meyer HE, Uszkoreit J, Eisenacher M, Suh J, Guénette SY, Röhner N, Kögel D, Theiss C, Marcus K, Müller T., Free PMC Article | 10/11/2014 |
| In classical mesial temporal sclerosis 1A, the expression of SV2 isoforms is altered with a marked decrease of SV2A paralleling synaptic loss. | Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis.
Crèvecoeur J, Kaminski RM, Rogister B, Foerch P, Vandenplas C, Neveux M, Mazzuferi M, Kroonen J, Poulet C, Martin D, Sadzot B, Rikir E, Klitgaard H, Moonen G, Deprez M. | 09/13/2014 |
| High SV2A expression is associated with breast cancer. | Synaptic vesicle protein 2 (SV2) isoforms.
Bandala C, Miliar-García A, Mejía-Barradas CM, Anaya-Ruiz M, Luna-Arias JP, Bazán-Méndez CI, Gómez-López M, Juárez-Méndez S, Lara-Padilla E. | 06/8/2013 |
| This study in the German population provides evidence, at a genetic level, for the involvement of the SV2A gene region in schizophrenia. | Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia.
Mattheisen M, Mühleisen TW, Strohmaier J, Treutlein J, Nenadic I, Alblas M, Meier S, Degenhardt F, Herms S, Hoffmann P, Witt SH, Giegling I, Sauer H, Schulze TG, Rujescu D, Nöthen MM, Rietschel M, Cichon S. | 03/23/2013 |
| Data report a combined modelling and mutagenesis study that successfully identifies another 11 residues in synaptic vesicle protein 2A that appear to be involved in ligand binding. | Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
Shi J, Anderson D, Lynch BA, Castaigne JG, Foerch P, Lebon F. | 01/21/2012 |
| expression of SV2A in tumor and peritumoral tissue is correlated to the clinical response to levetiracetam and predicts levetiracetam efficacy | Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
de Groot M, Aronica E, Heimans JJ, Reijneveld JC. | 10/1/2011 |
| the role of SV2A in epileptogenesis in patients with glial tumors is questionable | Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
de Groot M, Toering ST, Boer K, Spliet WG, Heimans JJ, Aronica E, Reijneveld JC., Free PMC Article | 05/31/2010 |
| The pattern of SV2A immunoreactivity with reduced neuropil expression and altered cellular and subcellular distribution suggests a possible contribution of SV2A to the epileptogenicity of these malformations of cortical development. | Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.
Toering ST, Boer K, de Groot M, Troost D, Heimans JJ, Spliet WG, van Rijen PC, Jansen FE, Gorter JA, Reijneveld JC, Aronica E. | 01/21/2010 |
| Botulinum toxin type A (BTA) inhibits the growth of LNCaP human PCa cells in vitro and in vivo. BTA acts on the cells by virtue of the BTA receptor, the SV2 protein. | Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.
Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, Rocchi P, Giusiano S, Elzayat EA, Corcos J. | 01/21/2010 |
| We found no association between genetic variation in SV2A and response to levetiracetam or epilepsy predisposition | No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
Lynch JM, Tate SK, Kinirons P, Weale ME, Cavalleri GL, Depondt C, Murphy K, O'Rourke D, Doherty CP, Shianna KV, Wood NW, Sander JW, Delanty N, Goldstein DB, Sisodiya SM. | 01/21/2010 |